A Guide to Integrating Emerging Therapies into Current Treatment Paradigms for Hepatocellular Carcinoma

A Guide to Integrating Emerging Therapies into Current Treatment Paradigms for Hepatocellular Carcinoma

On-Demand Webcast
Program Chair

Ghassan Abou-Alfa, MD, MBA
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Panelists

Lewis R. Roberts, MB, CHB, PHD
Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Riad Salem, MD, MBA
Professor of Radiology, Medicine and Surgery
Chief, Interventional Radiology
Northwestern University
Chicago, Illinois

Myron Schwartz, MD
Professor of Surgery
Icahn School of Medicine at Mount Sinai Medical Center
New York, New York

Intended Learners

This activity is designed for medical, radiological and surgical oncologists, gastroenterologists, and hepatologists.

Learning Objectives

At the completion of this activity, the participant will be better able to:

  • Discuss emerging agents, including immune checkpoint inhibitor therapies, that enhance survival for patients with HCC who have disease progression after sorafenib
  • Evauate PK-PD profiles, efficacy, and adverse event data that are emerging regarding newer TKIs and IO agents as monotherapy and/or in combination for management of HCC
  • Interpret recent results and ongoing clinical trials pertaining to therapeutic strategies designed to improve patients' outcomes in HCC
Activity Overview

This on-demand webcast is available with synchronized slides and video.

In order to be eligible for documentation of credit, participants must complete the pre-test, attend the full webinar, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Release date: August 30, 2018
Expiration date: August 30, 2019
Estimated time to complete: 1 hour

There is no fee associated with this activity.

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Provider


This activity is provided by Imedex®, LLC.

 

Continuing Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designated this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Planning Committee

The planning committee comprises Ghassan K. Abou-Alfa, MD, MBA; Anne Covey, MD; Kenneth Chavin, MD, PhD; Constantino Pena, MD; Lewis R. Roberts, MB, CHB, PHD; Riad Salem, MD, MBA; Myron Schwartz MD; Robert S. Dieter, MD, RVT, FACC; Susie Seaman, NP; Monalisa Singh, MD, PhD, and Susan Yarbrough, Imedex; and Kristin Ciszeski, MaryEllen Fama, Emily Gibson, Jennifer Ilcyn, and Randy Robbin, NACCME.

Independent Clinical Reviewer: Robert S. Dieter, MD, RVT, FACC, Loyola University Medicine, Chicago, Illinois 

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Abou-Alfa: Grant/Research Support --  Agios, Array, Astra Zeneca, Bayer, BMS, Casi, Celgene, Exelixis, Genentech, Incyte, Lilly, Mabvax, Medimmune, Momenta, Novartis, OncoMed Pharmaceuticals, Roche; Consulting -- Agios, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, BMS, Boston Scientifc, Carsgen, Celgene, Casi, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Gilead, Halozyme, Inovio, Ipsen, Merck, Onxeo, PCI Biotech, Roche, Sanofi, Servier, Silenseed, Sillajen, Sirtex, Vicus, Yakult

Dr. Covey:  Advisory Board -- Guerbet; Major Stock Shareholder -- Amgen, Guerbet

Dr. Peña: Consultant -- Boston Scientific, CR Bard, Halyard, Medtronic, WL Gore; Speakers’ Burearu- Boston Scientific, BTG, Cook Inc, CR Bard, Medtronic, Merit, Penumbra, Terumo

Dr. Roberts: Grant/Research Support -- Ariad, BTG, Gilead, Redhill, Wako; Consulting -- Axis, Medscape, OncLive, Wako; Advisory Board -- Bayer, Grail, Tavec

Dr. Salem: Consultant/Advisory Board -- BTG, Boston Scientific, Bristol-Myers Squibb, Dova Pharmaceuticals, Eisai, Merit

Dr. Chavin, Dr. Dieter, Dr. Schwartz, Monalisa Singh, Susan Yarbrough, Kristin Ciszeski, MaryEllen Fama, Emily Gibson, Jennifer Ilcyn, and Randy Robbin  have disclosed no relevant financial relationships with any commercial interests.

Dr. Schwartz will discuss the off-label use of nivolumab for neoadjuvant therapy

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by Imedex, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Imedex. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or Imedex . Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.